Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

With cardiovascular disease being the leading cause of morbidity and mortality worldwide,
effective and cost-efficient therapies to reduce cardiovascular risk are highly needed. Lipids …

PCSK9 degrades low-density lipoprotein cholesterol (LDL) receptors and subsequently
increases serum LDL cholesterol. Clinical trials show that inhibition of PCSK9 efficiently …

Atherosclerosis, the pathological basis of most cardiovascular disease (CVD), is closely
associated with cholesterol accumulation in the arterial intima. Excessive cholesterol is …

Foam cell formation and further accumulation in the subendothelial space of the vascular
wall is a hallmark of atherosclerotic lesions. Targeting foam cell formation in the …

The aim of this study was to investigate the mechanisms through which quercetin protects
against atherosclerosis (AS) in apoE‑/‑mice by regulating the expression of proprotein …

Background Cancer is emerging as a major problem globally, as it accounts for the second
cause of death despite medical advances. According to epidemiological and basic studies …

Abstract Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is involved in cholesterol
homeostasis. After binding to the complex low‐density lipoprotein (LDL)‐receptor, PCSK9 …

Cholesterol homeostasis is a highly regulated process in human body because of its several
functions underlying the biology of cell membranes, the synthesis of all steroid hormones …

Atherosclerosis, one of the life-threatening cardiovascular diseases (CVDs), has been
demonstrated to be a chronic inflammatory disease, and inflammatory and immune …